Search

Enter keywords, a title or a report id number below.

Order by Fax Ask a Question Printer Friendly PDF Brochure

Electronic (PDF)

Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the title.

EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00
Site License

Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access the title.

EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00
Enterprisewide

Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access the title.

EURO€ 1,153.00USD$ 1,500.00GBP£ 970.00AUD$ 1,467.00JPY¥ 148,099.00SEK 9 849,00CHF 1'414.00CAD$ 1,528.00

Live Chat Live Help Software for Website

Ovarian Cancer - Pipeline Review, H1 2012

Global Markets Direct, January 2012, Pages: 418

Ovarian Cancer – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Ovarian Cancer - Pipeline Review, H1 2012', provides an overview of the Ovarian Cancer therapeutic pipeline. This report provides information on the therapeutic development for Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ovarian Cancer. 'Ovarian Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Ovarian Cancer.
- A review of the Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Ovarian Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Ovarian Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Ovarian Cancer pipeline depth and focus of Ovarian Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Ovarian Cancer Therapeutic Products under Development, Key Players in Ovarian Cancer Therapeutics, Ovarian Cancer Pipeline Overview, Ovarian Cancer Pipeline, Ovarian Cancer Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Ovarian Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Ovarian Cancer
Ovarian Cancer Therapeutics under Development by Companies
Ovarian Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Ovarian Cancer Therapeutics – Products under Development by Companies
Ovarian Cancer Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Ovarian Cancer Therapeutics Development
Johnson & Johnson
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Amgen Inc.
Sanofi-Aventis
AstraZeneca PLC
Eli Lilly and Company
Viralytics Ltd.
GlaxoSmithKline plc
Tekmira Pharmaceuticals Corp.
Genentech, Inc.
Nektar Therapeutics
Daiichi Sankyo Company, Ltd
Merck & Co., Inc.
Micromet, Inc.
Generex Biotechnology Corporation
Takeda Pharmaceutical Company Limited
Bio-Path Holdings, Inc.
Millennium Pharmaceuticals, Inc.
Novartis AG
Viventia Biotechnologies Inc.
TRACON Pharmaceuticals, Inc.
Advanced Cancer Therapeutics
Oncolix, Inc.
OHR Pharmaceutical Inc.
RECEPTA Biopharma S.A.
Kyowa Hakko Kirin Pharma, Inc.
Vaxonco
Sentinel Oncology Limited
Mebiopharm Co., Ltd.
VectorLogics, Inc.
ISA Pharmaceuticals B.V.
Gradalis Inc.
Oncozyme Pharma Inc.
Ovarian Cancer – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AMG 386 - Drug Profile
Abagovomab - Drug Profile
OPAXIO - Drug Profile
MORAb-003 - Drug Profile
Paclical - Drug Profile
Telcyta - Drug Profile
NV06 - Drug Profile
Vargatef - Drug Profile
Tirazone - Drug Profile
Particulate Delivery - Drug Profile
Trabectedin - Drug Profile
Carboplatin + Thalidomide - Drug Profile
Amifostine Trihydrate - Drug Profile
Phenoxodiol + Carboplatin - Drug Profile
Bevacizumab + Carboplatin + Gemcitabine - Drug Profile
Carboplatin + Paclitaxel + Bevacizumab - Drug Profile
Carboplatin + Paclitaxel + Bevacizumab - Drug Profile
Oxaliplatin + Capecitabine + Bevacizumab - Drug Profile
Carboplatin + Taxol - Drug Profile
Cisplatin + Taxol - Drug Profile
Carboplatin + Gemcitabine + Paclitaxel - Drug Profile
Carboplatin + Paclitaxel - Drug Profile
Paclitaxel + Carboplatin + Topotecan - Drug Profile
Carboplatin + Ifosfamide - Drug Profile
Carboplatin + Ifosfamide + Whole Body Hyperthermia - Drug Profile
Carboplatin + Paclitaxel + Cediranib - Drug Profile
Carboplatin + Paclitaxel + Doxorubicin HCl Liposome - Drug Profile
Carboplatin + Paclitaxel + Gemcitabine - Drug Profile
Carboplatin + Topotecan Hydrochloride - Drug Profile
Carboplatin + Gemcitabine - Drug Profile
Carboplatin + Paclitaxel - Drug Profile
Carboplatin - Drug Profile
Bevacizumab + Carboplatin + Docetaxel + Paclitaxel - Drug Profile
Sodium Thiosulfate - Drug Profile
Paclitaxel - Drug Profile
Taxol + Paraplatin - Drug Profile
AMG 386 + Pegylated Liposomal Doxorubicin - Drug Profile
AMG 386 + Paclitaxel - Drug Profile
Carboplatin + Paclitaxel - Drug Profile
Treosulfan - Drug Profile
Carboplatin + Gemcitabine Hydrochloride + Paclitaxel - Drug Profile
Carboplatin + Liposomal Doxorubicin - Drug Profile
Ifosfamide + Paclitaxel - Drug Profile
Yondelis + DOXIL - Drug Profile
Avastin + Carboplatin + Paclitaxel - Drug Profile
Avastin + Carboplatin + Paclitaxel - Drug Profile
Avastin + Paclitaxel + Topotecan + Liposomal Doxorubicin - Drug Profile
Gemcitabine + Carboplatin - Drug Profile
Telcyta + Paraplatin - Drug Profile
Topotecan - Drug Profile
Karenitecin - Drug Profile
CAELYX + Carboplatin - Drug Profile
Paclitaxel + Carboplatin - Drug Profile
Doxorubicin + Carboplatin + Paclitaxel - Drug Profile
Cisplatin - Drug Profile
Cyclophosphamide + Cisplatin - Drug Profile
Bevacizumab + Cisplatin + Paclitaxel - Drug Profile
EC145 + Doxil - Drug Profile
Cisplatin - Drug Profile
Cisplatin + Carboplatin - Drug Profile
Avastin - Drug Profile
Filgrastim + Doxorubicin + Ifosfamide - Drug Profile
Doxorubicin + Carboplatin - Drug Profile
Paclitaxel + Carboplatin - Drug Profile
Docetaxel + Carboplatin - Drug Profile
Paclitaxel + Carboplatin - Drug Profile
Oxaliplatin + Capecitabine - Drug Profile
Carboplatin + Taxol - Drug Profile
Irinotecan + Cisplatin - Drug Profile
Irinotecan + Cisplatin - Drug Profile
Taxol + Paraplatin + Bevacizumab - Drug Profile
cediranib - Drug Profile
Paclitaxel + Carboplatin + Epirubicin - Drug Profile
Irinotecan + Cisplatin - Drug Profile
Votrient - Drug Profile
Tarceva - Drug Profile
Paclitaxel + AZD0530 - Drug Profile
Cisplatin + Cyclophosphamide + Tamoxifen - Drug Profile
Bevacizumab + Carboplatin + Paclitaxel - Drug Profile
Carboplatin + Pegylated Liposomal Doxorubicin - Drug Profile
OPT-821 + Polyvalent Antigen-KLH Conjugate Vaccine - Drug Profile
Cisplatin + Topotecan + Paclitaxel + Carboplatin - Drug Profile
Carboplatin + Pegylated Liposomal Doxorubicin - Drug Profile
Carboplatin + Glutathione + Paclitaxel - Drug Profile
bevacizumab + capecitabine + carboplatin + oxaliplatin + paclitaxel - Drug Profile
Carboplatin + Paclitaxel + Bevacizumab - Drug Profile
Cisplatin + Paclitaxel - Drug Profile
CT-2103 - Drug Profile
Cisplatin + Taxol - Drug Profile
Cisplatin + Adriamycin - Drug Profile
Pegylated Liposomal Doxorubicin + Trabectedin - Drug Profile
Ovarian Cancer Therapeutics – Drug Profile Updates
Ovarian Cancer Therapeutics – Discontinued Products
Ovarian Cancer Therapeutics - Dormant Products
Ovarian Cancer – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Ovarian Cancer, H1 2012
Products under Development for Ovarian Cancer – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Johnson & Johnson, H1 2012
Boehringer Ingelheim GmbH, H1 2012
F. Hoffmann-La Roche Ltd., H1 2012
Abbott Laboratories, H1 2012
Amgen Inc., H1 2012
Sanofi-Aventis, H1 2012
AstraZeneca PLC, H1 2012
Eli Lilly and Company, H1 2012
Viralytics Ltd., H1 2012
GlaxoSmithKline plc, H1 2012
Tekmira Pharmaceuticals Corp., H1 2012
Genentech, Inc., H1 2012
Nektar Therapeutics, H1 2012
Daiichi Sankyo Company, Ltd, H1 2012
Merck & Co., Inc., H1 2012
Micromet, Inc., H1 2012
Generex Biotechnology Corporation, H1 2012
Takeda Pharmaceutical Company Limited, H1 2012
Bio-Path Holdings, Inc., H1 2012
Millennium Pharmaceuticals, Inc., H1 2012
Novartis AG, H1 2012
Samyang Corporation, H1 2012
Aphios Corporation, H1 2012
ImClone Systems Incorporated, H1 2012
Eisai Co., Ltd., H1 2012
ImmunoGen, Inc., H1 2012
OSI Pharmaceuticals, Inc., H1 2012
Cell Therapeutics, Inc., H1 2012
Santaris Pharma A/S, H1 2012
Exelixis, Inc., H1 2012
Aduro BioTech, H1 2012
TopoTarget A/S, H1 2012
Karolinska Institutet, H1 2012
Poniard Pharmaceuticals, Inc., H1 2012
Oncogenex Pharmaceuticals, Inc., H1 2012
Dendreon Corporation, H1 2012
Thallion Pharmaceuticals Inc., H1 2012
Prima BioMed Limited, H1 2012
PharmaGap Inc., H1 2012
Quest PharmaTech Inc., H1 2012
Synta Pharmaceuticals Corp., H1 2012
Oasmia Pharmaceutical AB, H1 2012
Algeta ASA, H1 2012
RXi Pharmaceuticals Corporation, H1 2012
Rexahn Pharmaceuticals, Inc., H1 2012
MabVax Therapeutics, Inc., H1 2012
Morphotek, Inc., H1 2012
Oryzon, H1 2012
GANYMED Pharmaceuticals AG, H1 2012
Abiogen Pharma S.p.A., H1 2012
Glycotope GmbH, H1 2012
BioNumerik Pharmaceuticals, Inc., H1 2012
Indena S.p.A., H1 2012
Alethia Biotherapeutics Inc., H1 2012
Coronado Biosciences, Inc., H1 2012
Heat Biologics, Inc., H1 2012
MacroGenics, Inc., H1 2012
Fresenius Biotech GmbH, H1 2012
Azaya Therapeutics, Inc., H1 2012
CanBas Co., Ltd., H1 2012
Merrimack Pharmaceuticals, Inc., H1 2012
Spirogen Ltd., H1 2012
Neotropix, Inc., H1 2012
Conatus Pharmaceuticals Inc., H1 2012
CritiTech, Inc., H1 2012
BioCancell Therapeutics, Inc., H1 2012
Endocyte, Inc., H1 2012
Advenchen Laboratories, LLC, H1 2012
Onconova Therapeutics, Inc, H1 2012
MolMed S.p.A., H1 2012
Immunotope, Inc., H1 2012
Esperance Pharmaceuticals, Inc., H1 2012
Bolder Biotechnology, Inc., H1 2012
BiPar Sciences, Inc., H1 2012
ImmunoVaccine Technologies Inc., H1 2012
Welichem Biotech Inc., H1 2012
Angstrom Pharmaceuticals, Inc., H1 2012
Vaccinogen, Inc., H1 2012
Cancer Vaccines Limited, H1 2012
NewLink Genetics Corporation, H1 2012
TVAX Biomedical, LLC, H1 2012
Quintessence Biosciences, Inc., H1 2012
arGEN-X BV, H1 2012
Kinex Pharmaceuticals, LLC, H1 2012
Tigris Pharmaceuticals, Inc., H1 2012
Viventia Biotechnologies Inc., H1 2012
TRACON Pharmaceuticals, Inc., H1 2012
Advanced Cancer Therapeutics, H1 2012
Oncolix, Inc., H1 2012
OHR Pharmaceutical Inc., H1 2012
RECEPTA Biopharma S.A., H1 2012
Kyowa Hakko Kirin Pharma, Inc., H1 2012
Vaxonco, H1 2012
Sentinel Oncology Limited, H1 2012
Mebiopharm Co., Ltd., H1 2012
VectorLogics, Inc., H1 2012
ISA Pharmaceuticals B.V., H1 2012
Gradalis Inc., H1 2012
Oncozyme Pharma Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Ovarian Cancer Therapeutics – Drug Profile Updates
Ovarian Cancer Therapeutics – Discontinued Products
Ovarian Cancer Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Ovarian Cancer, H1 2012
Products under Development for Ovarian Cancer – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network

Viewing report

• ORDER BY FAX

• REGISTER

• SELECT SITE CURRENCY

Ovarian Cancer - Pipeline Review, H1 2012

Global Markets Direct, January 2012, Pages: 418

Customers who bought this item also bought

For enquiries please call us on: